Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 275805, 8 pages
Review Article

The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis

1Department of Nuclear Medicine, Renji Hospital, Jiaotong University, Shanghai 200127, China
2Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
3Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

Received 17 March 2013; Revised 13 June 2013; Accepted 2 July 2013

Academic Editor: Ignasi Carrio

Copyright © 2013 Yuyuan Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary material included 2 funnel graphs for potential publication bias in studies of I-FDG-PET on PFS( Figure S1) and OS (Figure S2) in DLBCL patients, and 1 forest plot(Figure S3) of four included studies in non-DLBCL (F-PET, OS).(PET: positron emission tomography, PFS: progression free survival, OS: overall survival, HR: hazard ratio; DLBCL: diffuse large B-cell lymphoma).

  1. Supplementary Material